Topical Administration of Gardenia jasminoides Extract Regulates Th2 Immunity in OVA-Induced Mice
A key feature of an allergic immune response is a T helper type 2 (Th2)-mediated response with production of allergen-specific IgE antibodies. Gardenia jasminoides extract with the crocin removed (GJExCR) has been shown to inhibit IgE-mediated allergic disease. To evaluate the efficacy and mechanism-of-action of this inhibition, GJExCR was used in an ovalbumin (OVA)-induced allergy model in BALB/C mice. Sensitization of BALB/C mice with OVA and aluminum hydroxide was performed on days 1 and 14 by intraperitoneal injection, followed by OVA challenge to the dorsal skin for 2 weeks before removal. Seven days post-challenge, mice were treated with GJExCR topically every day for 11 days. Enzyme-linked immunosorbent assay, flow cytometry analysis, real-time PCR, and western blot were performed to determine IgE and Th2 cytokine levels. Following OVA challenge, Th2 cytokine expression and both total and OVA-specific serum IgE levels increased, of which OVA-specific IgE and Th2 cytokine levels decreased after GJExCR treatment. Flow cytometry analysis revealed that GJExCR treatment decreased CD4+ and CD8+ T cell populations in the spleen and lymph nodes. In addition, treatment with GJExCR downregulated signal transducer and activator of transcription 1 (STAT1) activation and Th2 cytokine levels as compared to control. GJExCR containing geniposide downregulated STAT1 activation in HaCaT cells. These findings demonstrate that GJExCR exerts its anti-allergy effect via inhibition of STAT1 activation, thus regulating the immune response via modulation of Th2 cytokine release and IgE levels. Therefore, we propose GJExCR as a potential treatment for allergic hypersensitivity reactions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Cells - 12(2023), 6 vom: 20. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Park, Sun Haeng [VerfasserIn] |
---|
Links: |
---|
Themen: |
37341-29-0 |
---|
Anmerkungen: |
Date Completed 30.03.2023 Date Revised 11.04.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/cells12060941 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354852434 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM354852434 | ||
003 | DE-627 | ||
005 | 20231226063116.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/cells12060941 |2 doi | |
028 | 5 | 2 | |a pubmed24n1182.xml |
035 | |a (DE-627)NLM354852434 | ||
035 | |a (NLM)36980282 | ||
035 | |a (PII)941 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Park, Sun Haeng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Topical Administration of Gardenia jasminoides Extract Regulates Th2 Immunity in OVA-Induced Mice |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.03.2023 | ||
500 | |a Date Revised 11.04.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a A key feature of an allergic immune response is a T helper type 2 (Th2)-mediated response with production of allergen-specific IgE antibodies. Gardenia jasminoides extract with the crocin removed (GJExCR) has been shown to inhibit IgE-mediated allergic disease. To evaluate the efficacy and mechanism-of-action of this inhibition, GJExCR was used in an ovalbumin (OVA)-induced allergy model in BALB/C mice. Sensitization of BALB/C mice with OVA and aluminum hydroxide was performed on days 1 and 14 by intraperitoneal injection, followed by OVA challenge to the dorsal skin for 2 weeks before removal. Seven days post-challenge, mice were treated with GJExCR topically every day for 11 days. Enzyme-linked immunosorbent assay, flow cytometry analysis, real-time PCR, and western blot were performed to determine IgE and Th2 cytokine levels. Following OVA challenge, Th2 cytokine expression and both total and OVA-specific serum IgE levels increased, of which OVA-specific IgE and Th2 cytokine levels decreased after GJExCR treatment. Flow cytometry analysis revealed that GJExCR treatment decreased CD4+ and CD8+ T cell populations in the spleen and lymph nodes. In addition, treatment with GJExCR downregulated signal transducer and activator of transcription 1 (STAT1) activation and Th2 cytokine levels as compared to control. GJExCR containing geniposide downregulated STAT1 activation in HaCaT cells. These findings demonstrate that GJExCR exerts its anti-allergy effect via inhibition of STAT1 activation, thus regulating the immune response via modulation of Th2 cytokine release and IgE levels. Therefore, we propose GJExCR as a potential treatment for allergic hypersensitivity reactions | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Allergy | |
650 | 4 | |a Atopic dermatitis | |
650 | 4 | |a BALB/C mice | |
650 | 4 | |a Gardenia jasminoides extract | |
650 | 4 | |a cytokines | |
650 | 7 | |a Ovalbumin |2 NLM | |
650 | 7 | |a 9006-59-1 |2 NLM | |
650 | 7 | |a Cytokines |2 NLM | |
650 | 7 | |a Immunoglobulin E |2 NLM | |
650 | 7 | |a 37341-29-0 |2 NLM | |
700 | 1 | |a Song, Hyun-Kyung |e verfasserin |4 aut | |
700 | 1 | |a Ji, Kon-Young |e verfasserin |4 aut | |
700 | 1 | |a Jung, Dong Ho |e verfasserin |4 aut | |
700 | 1 | |a Jang, Seol |e verfasserin |4 aut | |
700 | 1 | |a Kim, Taesoo |e verfasserin |4 aut | |
700 | 1 | |a Kim, Ho Kyoung |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 12(2023), 6 vom: 20. März |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2023 |g number:6 |g day:20 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells12060941 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2023 |e 6 |b 20 |c 03 |